Record of data processing activity relating to Security Access Control System
Submitted by Anonymous (not verified) on 24 February 2026 - 10:00
Record of data processing activity relating to Security Access Control System
Product Management Service (PMS) information day 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 9 June 2026, 09:00 (CEST) to 9 June 2026, 13:00 (CEST)
Submitted by Anonymous (not verified) on 24 February 2026 - 8:32
Product Management Service (PMS) information day 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 9 June 2026, 09:00 (CEST) to 9 June 2026, 13:00 (CEST)
Agenda - PDCO agenda of the 24-27 February 2026 meeting
Submitted by Anonymous (not verified) on 24 February 2026 - 8:20
Agenda - PDCO agenda of the 24-27 February 2026 meeting
EMA/PE/0000257243
Submitted by Anonymous (not verified) on 23 February 2026 - 16:50
EMA/PE/0000257243
EMA/PE/0000231113
Submitted by Anonymous (not verified) on 23 February 2026 - 16:48
EMA/PE/0000231113
Human medicines European public assessment report (EPAR): Inluriyo, imlunestrant, Date of authorisation: 09/01/2026, Revision: 1, Status: Authorised
Submitted by Anonymous (not verified) on 23 February 2026 - 16:25
Human medicines European public assessment report (EPAR): Inluriyo, imlunestrant, Date of authorisation: 09/01/2026, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Efmody, hydrocortisone, Date of authorisation: 27/05/2021, Revision: 9, Status: Authorised
Submitted by Anonymous (not verified) on 23 February 2026 - 16:20
Human medicines European public assessment report (EPAR): Efmody, hydrocortisone, Date of authorisation: 27/05/2021, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Ogivri, trastuzumab, Date of authorisation: 12/12/2018, Revision: 13, Status: Authorised
Submitted by Anonymous (not verified) on 23 February 2026 - 16:12
Human medicines European public assessment report (EPAR): Ogivri, trastuzumab, Date of authorisation: 12/12/2018, Revision: 13, Status: Authorised
Natpar
Submitted by Anonymous (not verified) on 23 February 2026 - 16:00
Natpar
Human medicines European public assessment report (EPAR): Emblaveo, aztreonam,avibactam, Date of authorisation: 22/04/2024, Revision: 3, Status: Authorised
Submitted by Anonymous (not verified) on 23 February 2026 - 15:50
Human medicines European public assessment report (EPAR): Emblaveo, aztreonam,avibactam, Date of authorisation: 22/04/2024, Revision: 3, Status: Authorised